Loading patent…
AssigneeThe U.S.A., as represented by the Secretary, Department of Health and Human Services
InventorsZhaochun CHEN, Stephen H. LEPPLA, Mahtab MOAYERI, Suzanne U. EMERSON, Robert H. PURCELL
Estimating the term…
The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
1-13. (canceled)
An isolated nucleic acid comprising a nucleotide sequence encoding a polypeptide selected from the group consisting of:
17-18. (canceled)
A method for the treatment of anthrax disease comprising administering to a patient a therapeutically effective amount of a pharmaceutical preparation comprising a pharmaceutically acceptable carrier and a substantially pure polypeptide comprising:
A method for prophylaxis against anthrax disease comprising administering to a patient a prophylactically effective amount of a pharmaceutical preparation comprising a pharmaceutically acceptable carrier and a substantially pure polypeptide comprising:
21-24. (canceled)
Dependencies are inferred from the claim text.